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Preamble and Transition to ACC/AHA 
Guidelines to Reduce Cardiovascular Risk
The goals of the American College of Cardiology (ACC) and 
the American Heart Association (AHA) are to prevent cardio-
vascular diseases (CVD); improve the management of peo-
ple who have these diseases through professional education 
and research; and develop guidelines, standards, and policies 
that promote optimal patient care and cardiovascular health. 
Toward these objectives, the ACC and AHA have collaborated 
with the National Heart, Lung, and Blood Institute (NHLBI) 
and stakeholder and professional organizations to develop 
clinical practice guidelines for assessment of cardiovascular 
risk, lifestyle modifications to reduce cardiovascular risk, 
management of blood cholesterol in adults, and management 
of overweight and obesity in adults.
In 2008, the NHLBI initiated these guidelines by sponsoring 
rigorous systematic evidence reviews for each topic by expert 
panels convened to develop critical questions (CQs), interpret 
the evidence, and craft recommendations. In response to the 
2011 report from the Institute of Medicine on the develop-
ment of trustworthy clinical guidelines,1 the NHLBI Advisory 
Council recommended that the NHLBI focus specifically on 
reviewing the highest-quality evidence and partner with other 
organizations to develop recommendations.2,3 Accordingly, in 
June 2013 the NHLBI initiated collaboration with the ACC 
and AHA to work with other organizations to complete and 
publish the 4 guidelines noted above and make them avail-
able to the widest possible constituency. Recognizing that the 
Expert Work Group/Work Groups did not consider evidence 
beyond 2011 (except as specified in the methodology), the 
ACC, AHA, and collaborating societies plan to begin updat-
ing these guidelines starting in 2014.
The joint ACC/AHA Task Force on Practice Guidelines 
(Task Force) appointed a subcommittee to shepherd this tran-
sition, communicate the rationale and expectations to the writ-
ing panels and partnering organizations, and expeditiously 
publish the documents. The ACC/AHA and partner organi-
zations recruited a limited number of expert reviewers for 
fiduciary examination of content, recognizing that each docu-
ment had undergone extensive peer review by representatives 
of the NHLBI Advisory Council, key federal agencies, and 
scientific experts. Each writing panel responded to comments 
from these reviewers. Clarifications were incorporated where 
appropriate, but there were no substantive changes because 
the bulk of the content was undisputed.
Although the Task Force led the final development of these 
prevention guidelines, they differ from other ACC/AHA guide-
lines. First, as opposed to an extensive compendium of clinical 
information, these documents are significantly more limited in 
scope and focus on selected CQs on each topic, based on the 
highest-quality evidence available. Recommendations were 
derived from randomized trials, meta-analyses, and observa-
tional studies evaluated for quality and were not formulated 
when sufficient evidence was not available. Second, the text 
accompanying each recommendation is succinct, summa-
rizing the evidence for each question. The Full Panel/Work 
Group Reports include more detailed information about the 
evidence statements that serve as the basis for recommenda-
tions. Third, the format of the recommendations differs from 
other ACC/AHA guidelines. Each recommendation has been 
mapped from the NHLBI grading format to the ACC/AHA 
Classification of Recommendation/Level of Evidence (COR/
LOE) construct (Table 1) and is expressed in both formats. 
Because of the inherent differences in grading systems and 
the clinical questions driving the recommendations, alignment 
between the NHLBI and ACC/AHA formats is in some cases 
imperfect. Explanations of these variations are noted in the 
recommendation tables, where applicable.
In consultation with NHLBI, the policies adopted by the 
writing panels to manage relationships of authors with indus-
try and other entities (RWI) are outlined in the methods section 
of each panel report. These policies were in effect when this 
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effort began in 2008 and throughout the writing process and 
voting on recommendations, until the process was transferred 
to ACC/AHA in 2013. In the interest of transparency, the 
ACC/AHA requested that panel authors resubmit RWI disclo-
sures as of July 2013. Relationships relevant to this guideline 
are disclosed in Appendix 1. None of the ACC/AHA expert 
reviewers had relevant RWI (Appendix 2). See Appendix 3 for 
a list of abbreviations used in the guideline.
Systematic evidence reports and accompanying summary 
tables were developed by the expert panels and NHLBI. 
The guideline was reviewed by the ACC/AHA Task Force 
and approved by the ACC Board of Trustees, and the AHA 
Science Advisory and Coordinating Committee. In addi-
tion, ACC/AHA sought endorsement from other stakehold-
ers, including professional organizations. It is the hope of 
the writing panels, stakeholders, professional organizations, 
NHLBI, and Task Force that the guidelines will garner the 
widest possible readership for the benefit of patients, provid-
ers, and the public health.
These guidelines are meant to define practices that meet 
the needs of patients in most circumstances and are not a 
replacement for clinical judgment. The ultimate decision 
about care of a particular patient must be made by the 
healthcare provider and patient in light of the circum-
stances presented by that patient. As a result, situations 
might arise in which deviations from these guidelines may 
be appropriate. These considerations notwithstanding, in 
caring for most patients, clinicians can employ the recom-
mendations confidently to reduce the risks of atheroscle-
rotic cardiovascular disease (ASCVD) events.
See Tables 2 and 3 for an explanation of the NHLBI recom-
mendation grading methodology.
Table 1. Applying Classification of Recommendation and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines 
do not lend themselves to clinical trials. Even when randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is 
useful or effective.
*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior 
myocardial infarction, history of heart failure, and prior aspirin use. 
†For comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve 
direct comparisons of the treatments or strategies being evaluated.
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1. Introduction
1.1. Organization of the Work Group
The Risk Assessment Work Group (Work Group) was com-
posed of 11 members and 5 ex-officio members, including 
internists, cardiologists, endocrinologists, and experts in car-
diovascular epidemiology, biostatistics, healthcare manage-
ment and economics, and guideline development.
1.2. Document Review and Approval
A formal peer review process, which included 12 expert 
reviewers and representatives of federal agencies, was initially 
completed under the auspices of the NHLBI. This document 
was also reviewed by 3 expert reviewers nominated by the 
ACC and the AHA when the management of the guideline 
transitioned to the ACC/AHA. The ACC and AHA Reviewers’ 
RWI information is published in this document (Appendix 2).
This document was approved for publication by the govern-
ing bodies of the ACC and AHA and endorsed by the American 
Association of Cardiovascular and Pulmonary Rehabilitation, 
American Society for Preventive Cardiology, American 
Society of Hypertension, Association of Black Cardiologists, 
National Lipid Association, Preventive Cardiovascular Nurses 
Association, and WomenHeart: The National Coalition for 
Women With Heart Disease.
Table 2. NHLBI Grading of the Strength of Recommendations
Grade Strength of Recommendation*
A Strong recommendation
There is high certainty based on evidence that the net benefit†  
is substantial.
B Moderate recommendation
There is moderate certainty based on evidence that the net  
benefit is moderate to substantial, or there is high certainty  
that the net benefit is moderate.
C Weak recommendation
There is at least moderate certainty based on evidence that  
there is a small net benefit.
D Recommendation against
There is at least moderate certainty based on evidence that there 
is no net benefit or that risks/harms outweigh benefits.
E Expert opinion (“There is insufficient evidence or evidence 
is unclear or conflicting, but this is what the Work Group 
recommends.”)
Net benefit is unclear. Balance of benefits and harms cannot be 
determined because of no evidence, insufficient evidence, 
unclear evidence, or conflicting evidence, but the Work Group 
thought it was important to provide clinical guidance and make a 
recommendation. Further research is recommended in this area.
N No recommendation for or against (“There is insufficient  
evidence or evidence is unclear or conflicting.”)
Net benefit is unclear. Balance of benefits and harms cannot be 
determined because of no evidence, insufficient evidence, 
unclear evidence, or conflicting evidence, and the Work Group 
thought no recommendation should be made. Further research 
is recommended in this area.
*In most cases, the strength of the recommendation should be closely aligned 
with the quality of the evidence; however, under some circumstances, there 
may be valid reasons for making recommendations that are not closely aligned 
with the quality of the evidence (eg, strong recommendation when the evidence 
quality is moderate, such as smoking cessation to reduce cardiovascular disease 
risk or ordering an ECG as part of the initial diagnostic work-up for a patient 
presenting with possible MI). Those situations should be limited and the rationale 
explained clearly by the Work Group.
†Net benefit is defined as benefits minus risks/harms of the service/intervention.
ECG indicates electrocardiogram; MI, myocardial infarction; and NHLBI, 
National Heart, Lung, and Blood Institute.
Table 3. NHLBI Quality Rating of the Strength of Evidence
Type of Evidence Quality Rating*
•	Well-designed, well-executed† RCT that  
 adequately represent populations to which  
the results are applied and directly assess  
effects on health outcomes.
•	Meta-analyses of such studies.
Highly certain about the estimate of effect.  
  Further research is unlikely to change our  
confidence in the estimate of effect.
High
•	RCT with minor limitations‡ affecting confidence  
in, or applicability of, the results.
•	Well-designed, well-executed nonrandomized  
 controlled studies§ and well-designed,  
well-executed observational studies‖.
•	Meta-analyses of such studies.
Moderately certain about the estimate of effect.  
  Further research may have an impact on our 
confidence in the estimate of effect and may  
change the estimate.
Moderate
•	RCT with major limitations.
•	Nonrandomized controlled studies and  
 observational studies with major limitations affecting 
confidence in, or applicability of,  
the results.
•	Uncontrolled clinical observations without an  
 appropriate comparison group (eg, case series, case 
reports).
•	Physiological studies in humans.
•	Meta-analyses of such studies.
Low certainty about the estimate of effect. Further  
  research is likely to have an impact on our  
confidence in the estimate of effect and is likely  
to change the estimate.
Low
*In some cases, other evidence, such as large all-or-none case series (eg, 
jumping from airplanes or tall structures), can represent high- or moderate-quality 
evidence. In such cases, the rationale for the evidence rating exception should be 
explained by the Work Group and clearly justified.
†“Well-designed, well-executed” refers to studies that directly address the 
question; use adequate randomization, blinding, and allocation concealment; are 
adequately powered; use intention-to-treat analyses; and have high follow-up rates.
‡Limitations include concerns with the design and execution of a study that 
result in decreased confidence in the true estimate of the effect. Examples 
of such limitations include but are not limited to: inadequate randomization, 
lack of blinding of study participants or outcome assessors, inadequate power, 
outcomes of interest that are not prespecified for the primary outcomes, 
low follow-up rates, and findings based on subgroup analyses. Whether the 
limitations are considered minor or major is based on the number and severity 
of flaws in design or execution. Rules for determining whether the limitations 
are considered minor or major and how they will affect rating of the individual 
studies will be developed collaboratively with the methodology team.
§Nonrandomized controlled studies refer to intervention studies where 
assignment to intervention and comparison groups is not random (eg, quasi-
experimental study design).
‖Observational studies include prospective and retrospective cohort, case-
control, and cross-sectional studies.
NHLBI indicates National Heart, Lung, and Blood Institute; and RCT, 
randomized controlled trials.
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1.3. Charge to the Work Group
The Work Group was 1 of 3 work groups appointed by the 
NHLBI to develop its own recommendations and provide 
cross-cutting input to 3 Panels for updating guidelines on blood 
cholesterol, blood pressure (BP), and overweight/obesity. The 
Work Group was asked to examine the scientific evidence on 
risk assessment for initial ASCVD events and to develop an 
approach for quantitative risk assessment that could be used in 
practice and used or adapted by the risk factor panels (blood cho-
lesterol, hypertension, and obesity) in their guidelines and algo-
rithms. Specifically, the Work Group was charged with 2 tasks:
1. To develop or recommend an approach to quantitative 
risk assessment that could be used to guide care; and
2. To use systematic review methodology to pose and address 
a small number of questions judged to be critical to refin-
ing and adopting risk assessment in clinical practice.
1.4. Methodology and Evidence Review
This guideline is based on the Full Work Group Report 
supplement, which is provided as a supplement to the 
guideline. The Full Work Group Report supplement con-
tains background and additional material related to con-
tent, methodology, evidence synthesis, rationale, and 
references and is supported by the NHLBI Systematic 
Evidence Review, which can be found at (http://www.
nhlbi.nih.gov/guidelines/cvd_adult/risk_assessment/). 
These documents also describe the process for the develop-
ment of novel, comprehensive multivariable risk equations for 
the prediction of 10-year risk of development of ASCVD in 
non-Hispanic African-American and non-Hispanic white men 
and women from 40 to 79 years of age. These equations were 
developed from several long-standing population-based cohort 
studies funded by the NHLBI. Ten-year risk was defined as 
the risk of developing a first ASCVD event, defined as non-
fatal myocardial infarction or coronary heart disease (CHD) 
death or fatal or nonfatal stroke, over a 10-year period among 
people free from ASCVD at the beginning of the period.
In addition, through evaluation of evidence developed by 
systematic reviews of the literature, the Work Group addressed 
the following 2 CQs:
 CQ1. “What is the evidence with regard to reclas-
sification or contribution to risk assessment when 
high-sensitivity C-reactive protein (hs-CRP), apo-
lipoprotein B (ApoB), glomerular filtration rate, 
microalbuminuria, family history, cardiorespiratory 
fitness, ankle-brachial index (ABI), carotid intima-
media thickness (CIMT), or coronary artery calcium 
(CAC) score is considered in addition to the variables 
that are in the traditional risk scores?”
 CQ2. “Are models constructed to assess the long-term 
(≥15 years or lifetime) risk of a first cardiovascular 
disease (CVD) event in adults effective in assessing 
variation in long-term risk among adults at low and/
or intermediate short-term risk, whether analyzed 
separately or in combination?”
The evidence and recommendations in the guideline focus 
on the large proportion of the adult population without clinical 
signs or symptoms of ASCVD who merit evaluation for the pri-
mary prevention of ASCVD. They do not apply to those with 
clinically manifest ASCVD, who require secondary prevention 
approaches, or to highly-selected patient subgroups, such as 
those with symptoms suggestive of CVD, who require diagnos-
tic strategies rather than risk assessment. Furthermore, these rec-
ommendations were not developed for use in specific subgroups 
of asymptomatic individuals at unusually high risk, such as 
those with genetically determined extreme values of traditional 
risk factors (eg, patients with familial hypercholesterolemia).
2. Risk Assessment: Recommendations
See Table 4 for a summary of the recommendations for risk 
assessment.
3. Approach to Risk Assessment
In addressing its charge, the Work Group recognized the need 
for a risk assessment approach that was based on the types 
of data that primary care providers could easily collect and 
that could be implemented in routine clinical practice. After 
deliberation, the Work Group endorsed the existing and 
widely used paradigm of matching the intensity of preventive 
efforts with the individual’s absolute risk.23,24 The Work Group 
acknowledges that none of the risk assessment tools or novel 
risk markers examined in the present document have been for-
mally evaluated in randomized controlled trials of screening 
strategies with clinical events as outcomes. Nevertheless, this 
approach balances an understanding of an individual’s abso-
lute risk of CVD and potential treatment benefits against the 
potential absolute risks for harm from therapy. With the use of 
this framework, treatment can be targeted to those most likely 
to benefit without undue risk of harm, in the context of a “risk 
discussion.” A risk discussion could include the assessment 
of the patient’s risk of ASCVD, as well as potential benefits, 
negative aspects, risks, and patient preferences with regard to 
initiation of relevant preventive therapies.
By its nature, such an approach requires a platform for reli-
able quantitative estimation of absolute risk based on data 
from representative population samples. It is important to note 
that risk estimation is based on group averages, which are 
then applied to individual patients in practice. This process is 
admittedly imperfect; no one has 10% or 20% of a heart attack 
during a 10-year period. Individuals with the same estimated 
risk will either have or not have the event of interest, and only 
those patients who are destined to have an event can have their 
event prevented by therapy. The criticism of the risk-estima-
tion approach to treatment decision making also applies to the 
alternative, and much less efficient approach, of checking the 
patient’s characteristics against numerous and complex inclu-
sion and exclusion criteria for a potentially large number of 
pertinent trials. Only a small fraction of trial participants have 
events, and only a fraction of these events are prevented by 
therapy. Using either approach, the clinician must apply the 
average results obtained from groups of patients to the indi-
vidual patient in practice.
Given the modification and adoption of the Framingham 
10-year risk score for CHD risk assessment by the Third 
Report of the National Cholesterol Education Program Expert 
Work Group on Diagnosis, Evaluation, and Treatment of High 
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Blood Cholesterol in Adults (Adult Treatment Panel III)24 and 
the uptake of this algorithm by practice sites across the United 
States, the Work Group began by discussing the value of retain-
ing this algorithm. In collaboration with other NHLBI panels, 
the Work Group decided not to use this algorithm in its 2013 
recommendations because of the algorithm's derivation in an 
exclusively white sample population and the limited scope of 
the outcome (in determining CHD alone). Rather, the Work 
Group derived risk equations from community-based cohorts 
that are broadly representative of the US population of whites 
and African Americans, and the Work Group focused on estima-
tion of first hard ASCVD events (defined as first occurrence of 
nonfatal myocardial infarction, CHD death, or fatal or nonfatal 
stroke) as the outcome of interest because they were deemed to 
be of greater relevance to both patients and providers. The focus 
on hard ASCVD, rather than CHD alone, is also consistent with 
evidence reviewed in a statement from the AHA and American 
Stroke Association calling for the inclusion of ischemic stroke 
in the outcome of interest for CVD risk assessment.25
Numerous multivariable risk scores and equations have 
been derived and published (Appendix 6; for more details, 
see the Full Work Group Report supplement). As part of its 
deliberations, the Work Group considered previously pub-
lished risk scores with validation in NHLBI cohort data as 
one possible approach. However, several persistent concerns 
with existing risk equations were identified, including non-
representative or historically dated populations, limited ethnic 
diversity, narrowly defined endpoints, endpoints influenced 
by provider preferences (eg, elective revascularizations), and 
endpoints with poor reliability (eg, angina and heart failure). 
Given the inherent limitations of existing scores, the Work 
Group judged that a new risk score was needed to address 
some of the deficiencies of existing scores—for example, the 
need for a population sample that approaches, to the degree 
possible, the ideal sample for algorithm development and 
closely represents the US population.
Data are sparse on the use and impact of absolute risk 
scores in clinical practice in primary-prevention settings.26 
Table 4. Summary of Recommendations for Risk Assessment
Recommendations NHLBI Grade
NHLBI 
Evidence 
Statements ACC/AHA COR ACC/AHA LOE
Assessment of 10-Year Risk of a First Hard ASCVD Event
1. The race- and sex-specific Pooled Cohort Equations* to predict 10-year  
  risk of a first hard ASCVD event should be used in non-Hispanic African 
Americans and non-Hispanic whites, 40–79 years of age.
B (Moderate) N/A I B4–8
2. Use of the sex-specific Pooled Cohort Equations for non-Hispanic whites  
  may be considered for estimation of risk in patients from populations  
other than African Americans and non-Hispanic whites.
E (Expert Opinion) N/A IIb C
CQ1: Use of Newer Risk Markers After Quantitative Risk Assessment
1. If, after quantitative risk assessment, a risk-based treatment decision  
  is uncertain, assessment of ≥1 of the following—family history, hs-CRP,  
CAC score, or ABI—may be considered to inform treatment decision making.
E (Expert Opinion) Appendix 4 IIb† B9–17
2. Routine measurement of CIMT is not recommended in clinical practice  
 for risk assessment for a first ASCVD event.
N (No recommendation  
for or against)
Appendix 4 III: No Benefit† B12,16,18
3. The contribution of ApoB, CKD, albuminuria, and cardiorespiratory  
 fitness to risk assessment for a first ASCVD event is uncertain at present.
N (No recommendation  
for or against)
Appendix 4 — —
CQ2: Long-Term Risk Assessment
1. It is reasonable to assess traditional ASCVD risk factors‡ every 4–6 years  
  in adults 20–79 years of age who are free from ASCVD and to estimate  
10-year ASCVD risk every 4–6 years in adults 40–79 years of age who  
are free from ASCVD.
B (Moderate) Appendix 5
CQ2/ES7
IIa B19,20
2. Assessment of 30-year or lifetime ASCVD risk on the basis of  
  traditional risk factors‡ may be considered in adults 20–59 years  
of age who are free from ASCVD and are not at high short-term risk.
C (Weak) Appendix 5
CQ2/ES2,
CQ2/ES3,
CQ2/ES4,
CQ2/ES5,
CQ2/ES6
IIb C20–22
A downloadable spreadsheet enabling estimation of 10-year and lifetime risk of ASCVD and a Web-based calculator is available at http://my.americanheart.org/
cvriskcalculator and http://www.cardiosource.org/en/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/2013-Prevention-Guideline-Tools.aspx.
*Derived from the ARIC (Atherosclerosis Risk in Communities) study,8 Cardiovascular Health Study,5 CARDIA (Coronary Artery Risk Development in Young Adults) 
study,7 and Framingham original and offspring cohorts.4,6
†Based on new evidence reviewed during ACC/AHA update of evidence.
‡Age, sex, total cholesterol, high-density lipoprotein cholesterol, systolic BP, use of antihypertensive therapy, diabetes, and current smoking.
ABI indicates ankle-brachial index; ACC, American College of Cardiology; AHA, American Heart Association; ApoB, apolipoprotein B; ASCVD, atherosclerotic 
cardiovascular disease; BP, blood pressure; CAC, coronary artery calcium; CIMT, carotid intima-media thickness; CKD, chronic kidney disease; COR, Class of 
Recommendation; CQ, critical question, ES, evidence statement; hs-CRP, high-sensitivity C-reactive protein; LOE, Level of Evidence; NHLBI, National Heart, Lung, and 
Blood Institute; and —, not applicable.
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Two systematic reviews, based on few studies, support the 
conclusion that risk assessment, combined with counseling, 
is associated with favorable but modest changes in patient 
knowledge and intention to change and in provider prescrib-
ing behavior and risk factor control.27,28 No data are available 
on hard event outcomes. The Work Group specifically calls for 
research in this area (Section 8).
The Work Group notes that the “2009 ACCF/AHA Performance 
Measures for the Primary Prevention of Cardiovascular Disease 
in Adults” specifically recommended use of global CVD risk 
estimation in clinical practice.29 Likewise, the US Preventive 
Services Task Force recommendations for aspirin,30 the NHLBI 
Adult Treatment Panel III recommendations,24 and European31 
and Canadian32,33 guidelines for primary prevention of CVD, 
among others, have all recommended the use of absolute risk 
assessment for decision making about the intensity of lifestyle 
and pharmacological preventive interventions. Risk scores have 
been implemented in practice through paper scoring sheets and, 
increasingly, through Web sites and downloadable applications. 
The electronic medical record can be adapted to estimate abso-
lute risks automatically by using patient data and published 
equations, and it is anticipated that risk estimation with this tech-
nology will become a mainstream application of the current and 
future risk algorithms.
4. Development of New Pooled 
Cohort ASCVD Risk Equations
Having made the decision to develop new equations to esti-
mate the 10-year risk of developing a first ASCVD event, the 
Work Group used the best available data from community-
based cohorts of adults, with adjudicated endpoints for CHD 
death, nonfatal myocardial infarction, and fatal or nonfatal 
stroke. Cohorts that included African-American or white par-
ticipants with at least 12 years of follow-up were included. 
Data from other racial/ethnic groups were insufficient, pre-
cluding their inclusion in the final analyses. The final pooled 
cohorts included participants from several large, racially 
and geographically diverse, modern NHLBI-sponsored 
cohort studies, including the ARIC (Atherosclerosis Risk in 
Communities) study,8 the Cardiovascular Health Study,5 and 
the CARDIA (Coronary Artery Risk Development in Young 
Adults) study,7 combined with applicable data from the 
Framingham Original and Offspring Study cohorts.4,6
The Work Group used state-of-the-art statistical methods to 
derive and internally validate the Pooled Cohort Equations, 
which provide sex- and race-specific estimates of the 10-year 
risk of ASCVD for African-American and white men and 
women 40 to 79 years of age. The variables that statistically 
merit inclusion in the risk assessment equations are age, total 
cholesterol, high-density lipoprotein cholesterol, systolic BP 
(including treated or untreated status), diabetes mellitus (dia-
betes), and current smoking status.
An expanded description of the derivation and validation of 
the Pooled Cohort Equations, as well as the means for imple-
menting them in clinical practice, is provided in Appendix 
7. Additional details are provided in the Full Work Group 
Report supplement. A specific clinical vignette is also pro-
vided as an example in Appendix 7. In the clinical vignette, 
the 10-year risk is calculated for a patient 55 years of age who 
is a nonsmoker without diabetes, and with total cholesterol 
level of 213 mg/dL, high-density lipoprotein cholesterol level 
of 50 mg/dL, and untreated systolic BP of 120 mm Hg. With 
these values used in the Pooled Cohort Equations, the pre-
dicted 10-year ASCVD risks are 2.1% for white women, 3.0% 
for African-American women, 5.3% for white men, and 6.1% 
for African-American men.
Numerous other potential risk markers were considered 
for inclusion in the Pooled Cohort Equations: for many, no 
additional utility was demonstrated when they were included; 
for others, data are insufficient at the present time to deter-
mine their additional value. The equations were also assessed 
in external validation studies with data from other available 
cohorts. Other than the Framingham CHD risk score (and its 
derivative ATP III risk assessment profile) and the European 
SCORE (System for Cardiac Operative Risk Evaluation) algo-
rithm for CVD death, these equations have been subjected to 
more rigorous validation than other currently available equa-
tions, and they are the only risk assessment equations that 
include significant numbers of African Americans and that 
focus on estimation of 10-year risk of the clinically relevant 
endpoint of ASCVD. The Work Group specifically calls for 
further research to develop similar equations applicable to 
other ethnic groups, to validate the utility of the Pooled Cohort 
Equations in diverse primary-prevention settings, and to assess 
the potential benefit of novel risk markers when added to these 
equations, so that the equations maybe modified or expanded 
over time as new data become available.
4.1. Recommendations for Assessment of 10-Year 
Risk of a First Hard ASCVD Event
Recommendation 1. The race- and sex-specific Pooled Cohort 
Equations* to predict 10-year risk of a first hard ASCVD 
event should be used in non-Hispanic African Americans and 
non-Hispanic whites, 40 to 79 years of age.
NHLBI Grade: B (Moderate); ACC/AHA COR: I; LOE: B
Recommendation 2. Use of the sex-specific Pooled Cohort 
Equations for non-Hispanic whites may be considered for 
estimation of risk in patients from populations other than 
African Americans and non-Hispanic whites.
NHLBI Grade: E (Expert Opinion); ACC/AHA COR: IIb; 
LOE: C
A Web-based application enabling estimation of 10-year and life-
time risk of ASCVD is available at http://my.americanheart.org/
cvriskcalculator and http://www.cardiosource.org/en/Science-
And-Quality/Practice-Guidelines-and-Quality-Standards/2013-
Prevention-Guideline-Tools.aspx.
5. Implications for Risk Assessment
A range of estimated 10-year risk of a first hard ASCVD event 
is illustrated in the Full Work Group Report supplement (Tables 
8 through 11), across a broad range of risk factor burdens for 
*Ten-year risk was defined as the risk of developing a first ASCVD 
event, defined as nonfatal myocardial infarction, CHD death, or fatal or 
nonfatal stroke, over a 10-year period among people free from ASCVD at 
the beginning of the period.
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selected combinations of the risk factors in sex–race groups 
(African-American and white women and men). The estimated 
risks are specific to defined combinations of the risk factors 
and demonstrate how they vary over a broad spectrum of 
potential profiles. Risk factor levels that are more adverse than 
those shown in these tables should always be associated with a 
higher estimated risk. For example, if a given risk factor com-
bination indicates an estimated 10-year risk of hard ASCVD of 
8%, but a patient has a higher level of systolic BP or total cho-
lesterol, or a lower level of high-density lipoprotein cholesterol, 
than shown for that table cell, then the estimated risk would be 
≥8%. Because the estimated probabilities can become unstable 
when approaching the limits of the sample data, the risk prob-
abilities are truncated at 1% and 30%. The proportions of the 
US adult population, 40 to 79 years of age, in selected strata of 
estimated 10-year risk of hard ASCVD events, are shown over-
all and by sex and race/ethnicity in Table 5. When compared 
with non-Hispanic whites, estimated 10-year risk of ASCVD 
is generally lower in Hispanic-American and Asian-American 
populations and higher in American-Indian populations;34,35 
hence, the lack of race/ethnicity-specific risk algorithms is an 
important gap in our efforts to understand and prevent ASCVD 
in these populations. Although the development of algorithms 
specific to these racial/ethnic groups is encouraged, in the 
interim, providers may consider using the equations for non-
Hispanic whites for these patients. When doing so, the esti-
mated risks may be overestimates, especially for Hispanic and 
Asian Americans.
6. CQs and Systematic Evidence Review
6.1. Critical Question 1
“What is the evidence with regard to reclassification or 
contribution to risk assessment when hs-CRP, ApoB, 
glomerular filtration rate, microalbuminuria, family 
history, cardiorespiratory fitness, ABI, CAC, or CIMT 
is considered in addition to the variables that are in the 
traditional risk scores?”
The concept of matching the intensity of risk factor manage-
ment to the estimated risk of CVD has been well established 
since the 27th Bethesda Conference in 1996.23 As a conse-
quence, widespread attention has focused on the accuracy 
and reliability of risk assessment. Claims that a minority of 
the risk of CVD can be explained by the major traditional 
risk factors or that most patients presenting with CHD have 
no elevated traditional risk factors have been disproved.36,37 
Nonetheless, the desire to improve existing quantitative risk-
estimation tools has helped to stimulate and maintain interest 
in the search for new risk markers for CVD that might further 
enhance risk assessment.
CQ1 was developed to address whether newer risk mark-
ers have been identified that actually improve risk assessment 
enough to warrant routine measurement in clinical practice. 
This question applies to risk assessment in the general pop-
ulation—that is, the typical asymptomatic adult in routine 
clinical practice. This question does not address other highly 
selected patient subgroups, such as those with symptoms sug-
gestive of CVD.
CQ1 was addressed through 2 independent approaches. 
First, in the process of developing the Pooled Cohort 
Equations, the additional risk markers listed in CQ1 were 
tested for inclusion in the model if they were available in the 
databases and could be evaluated on the basis of at least 10 
years of follow-up. A review of meta-analyses and systematic 
reviews published before September 19, 2013, was conducted 
in 2 stages. In the first stage, meta-analyses and systematic 
reviews published before April 2011 were identified and 
reviewed. In a second stage, conducted to update the evidence 
base before publication, additional meta-analyses and sys-
tematic reviews published before September 19, 2013, were 
identified and reviewed against the same criteria applied in the 
first stage. The reliance on published meta-analyses to evalu-
ate novel biomarkers is a conservative approach that helps 
avoid the influence of positive publication bias that can occur 
early in the evaluation of a novel association and assures that 
we relied on a mature body of evidence.38
Members of the Work Group proposed an initial list of 
novel risk markers for inclusion in CQ1, which was then pri-
oritized during several rounds of discussion. In selecting the 
final list, the Work Group gave priority to factors that have 
engendered substantial discussion in the scientific community 
and that could be reasonably considered as potentially feasible 
for widespread population use by primary care providers in 
routine clinical settings in the United States. In these delibera-
tions, the Work Group considered availability, cost, assay reli-
ability, and risks of the test or downstream testing. The final 
list of new risk markers to be evaluated included several blood 
and urine biomarkers (hs-CRP, ApoB, creatinine [or estimated 
glomerular filtration rate], and microalbuminuria), several 
measures of subclinical cardiovascular disease (CAC, CIMT, 
and ABI), family history, and cardiorespiratory fitness. Other 
novel potential screening tools maybe the subject of future 
guideline updates. Guidance published by Hlatky et al39 was 
considered during discussion of the utility of incorporating 
these new risk factors into routine risk assessment. Special 
attention was given to the additional value these markers con-
tributed to risk assessment in terms of discrimination, calibra-
tion, reclassification, and cost-effectiveness, in the context of 
any potential harm.
6.1.1. Summary of Systematic Reviews and  
Meta-Analyses for CQ1
Thirteen systematic review articles or meta-analyses met the 
inclusion/exclusion criteria.9–18,40–42 Publication dates ranged 
from 2008 to 2013. The Work Group reviewed the 13 sys-
tematic reviews and meta-analyses and created a table to list 
their key findings (Appendix 4). None of these markers has 
been evaluated as a screening test in randomized controlled 
trials with clinical events as outcomes. On the basis of current 
(limited) evidence, it is the opinion of the Work Group that 
among the novel risk markers, assessments of family history 
of premature CVD, as well as measurement of hs-CRP, CAC, 
and ABI, show some promise for clinical utility. Table 6 pro-
vides expert opinion on thresholds of these measures that may 
be considered for clinical decision making.
The Work Group notes that the review by Peters et al16 pro-
vides evidence to support the contention that measuring CAC is 
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likely to be the most useful of the current approaches to improv-
ing risk assessment among individuals found to be at interme-
diate risk after formal risk assessment. Furthermore, the Work 
Group recognizes that the “2010 ACCF/AHA Guideline for 
Assessment of Cardiovascular Risk in Asymptomatic Adults” 
made recommendations for CAC testing.43 However, the Work 
Group notes that the outcomes in the studies reviewed by Peters 
et al16 and by Greenland et al43 were CHD outcomes, not hard 
ASCVD events that included stroke; hence, uncertainty remains 
about the contribution of CAC assessment to estimation of 
10-year risk of first hard ASCVD events after formal risk assess-
ment with the new Pooled Cohort Equations. Furthermore, 
Table 5. Distribution of Estimated 10-Year Risk of a First Hard ASCVD Event in the CVD-Free, Nonpregnant US Population, 40 to 79 
Years of Age, by Sex and Race/Ethnicity*
Predicted 10-Year Risk of Hard ASCVD Event
<2.5% 2.5%–4.9% 5.0%–7.4% 7.5%–9.9% 10.0%–14.9% 15.0%–19.9% ≥20.0%
Total
% (95% CI) 33.4 (31.2–35.5) 21.0 (19.4–22.7) 12.7 (11.4–14.0) 7.4 (6.5–8.3) 8.9 (8.1–9.6) 6.3 (5.6–7.1) 10.2 (9.5–11.0)
n 33 534 000 21 151 000 12 766 000 7 470 000 8 940 000 6 380 000 10 300 000
Sex
Men
% (95% CI) 17.4 (15.2–19.7) 22.7 (20.3–25.1) 15.6 (13.8–17.4) 10.1 (8.5–11.6) 12.1 (10.7–13.5) 8.8 (7.4–10.2) 13.3 (12.1–14.4)
n 8 386 000 10 950 000 7 511 000 4 847 000 5 849 000 4 248 000 6 388 000
Women
% (95% CI) 48.0 (44.8–51.3) 19.5 (17.3–21.6) 10.0 (8.3–11.8) 5.0 (3.8–6.2) 5.9 (5.1–6.7) 4.1 (3.4–4.7) 7.5 (6.5–8.4)
n 25 148 000 10 200 000 5 256 000 2 622 000 3 091 000 2 131 000 3 912 000
Race/Ethnicity
White
Men
% (95% CI) 18.0 (15.0–21.1) 22.4 (19.4–25.3) 15.7 (13.3–18.1) 10.0 (8.2–11.8) 11.7 (9.9–13.5) 8.7 (7.0–10.4) 13.6 (12.3–14.9)
n 6 467 000 8 016 000 5 616 000 3 584 000 4 189 000 3 112 000 4 870 000
Women
% (95% CI) 47.1 (43.0–51.1) 20.4 (17.7–23.0) 10.7 (8.6–12.8) 5.1 (3.6–6.7) 5.5 (4.6–6.5) 4.1 (3.4–4.9) 7.1 (5.9–8.2)
n 18 175 000 7 863 000 4 136 000 1 984 000 2 132 000 1 596 000 2 725 000
African American
Men
% (95% CI) 1.4 (0.3–2.6) 23.9 (19.9–28.0) 20.6 (17.0–24.2) 11.8 (8.8–14.8) 17.4 (14.3–20.5) 11.1 (8.2–13.9) 13.8 (11.0–16.7)
n 60 000 1 008 000 866 000 495 000 731 000 466 000 583 000
Women
% (95% CI) 36.5 (32.4–40.6) 18.7 (15.6–21.8) 10.9 (8.6–13.2) 6.5 (5.0–7.9) 9.4 (7.2–11.7) 5.7 (4.2–7.2) 12.3 (9.5–15.0)
n 1 921 000 985 000 572 000 339 000 496 000 300 000 645 000
Hispanic
Men
% (95% CI) 24.0 (19.8–28.1) 22.1 (17.9–26.2) 13.2 (10.8–15.6) 10.6 (8.1–13.0) 11.4 (9.9–12.9) 6.2 (4.6–7.9) 12.6 (9.4–15.7)
n 1 303 000 1 200 000 718 000 574 000 619 000 339 000 683 000
Women
% (95% CI) 59.4 (54.3–64.4) 14.5 (11.5–17.5) 7.5 (5.4–9.6) 4.5 (2.6–6.4) 4.9 (3.4–6.5) 3.0 (2.0–3.9) 6.3 (4.7–7.9)
n 3 293 000 803 000 418 000 248 000 273 000 164 000 347 000
Others
Men
% (95% CI) 20.8 (10.8–30.7) 27.1 (18.0–36.3) 11.6 (4.9–18.2) 7.2 (0.6–13.8) 11.5 (4.5–18.6) 12.3 (5.9–18.8) 9.4 (3.0–15.8)
n 555 000 726 000 310 000 193 000 309 000 330 000 251 000
Women
% (95% CI) 59.8 (50.2–69.3) 18.6 (10.8–26.5) 4.4 (0–8.7) 1.7 (0–3.5) 6.4 (2.1–10.7) 2.4 (0.4–4.5) 6.7 (2.3–11.0)
n 1 757 000 548 000 128 000 49 000 188 000 71 000 195 000
*Data derived by applying the Pooled Cohort Equations to the National Health and Nutrition Examinations Surveys, 2007–2010 (N=5367, weighted to 100 542 000 
US population).
ASCVD indicates atherosclerotic cardiovascular disease; and CVD, cardiovascular disease.
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issues of cost and radiation exposure related to measuring CAC 
were discussed, resulting in some uncertainty about potential 
risks of more widespread screening, which resulted in a decision 
in the present guideline to make assessment of CAC an ACC/
AHA COR IIb recommendation among individuals for whom 
a risk-based treatment decision is uncertain after formal risk 
estimation. The Work Group notes that this ACC/AHA COR 
IIb recommendation is consistent with the recommendations 
in the 2010 ACCF/AHA guideline43 for patients with a 10-year 
CHD risk of <10%, as well as for many other patients, because 
of the lower risk threshold (7.5% 10-year risk of a first hard 
ASCVD event) adopted by the “2013 ACC/AHA Guideline on 
the Treatment of Blood Cholesterol to Reduce Atherosclerotic 
Cardiovascular Risk in Adults”44 for recommending initiation 
of statin therapy for ASCVD risk reduction.
Furthermore, it was noted that measurement of ApoB, albu-
minuria, glomerular filtration rate, or cardiorespiratory fitness 
is of uncertain value. Finally, the Work Group judged that the 
evidence provided by Den Ruijter et al,18 reviewed during the 
ACC/AHA update period, in combination with the concerns 
about measurement quality, provided sufficient rationale to 
recommend against measuring CIMT in routine clinical prac-
tice for risk assessment for a first ASCVD event. If any of 
the 9 markers considered in the present report is assessed in 
selected patients, the use of the information to guide treatment 
decisions will require sound clinician judgment and should be 
based on shared decision making.
6.1.2. Recommendations for CQ1: Use of Newer Risk 
Markers After Quantitative Risk Assessment
Recommendation 1. If, after quantitative risk assessment, 
a risk-based treatment decision is uncertain, assessment of 
1 or more of the following—family history, hs-CRP, CAC 
score, or ABI—may be considered to inform treatment deci-
sion making.
NHLBI Grade: E (Expert Opinion); ACC/AHA COR: IIb†, 
LOE: B†
Recommendation 2. Routine measurement of CIMT is not 
recommended in clinical practice for risk assessment for a first 
ASCVD event.
NHLBI Grade: N (No recommendation for or against); 
ACC/AHA COR III: No Benefit†, LOE: B
Recommendation 3. The contribution of ApoB, chronic kid-
ney disease, albuminuria, and cardiorespiratory fitness to risk 
assessment for a first ASCVD event is uncertain at present.
NHLBI Grade: N (No recommendation for or against)
6.2. Critical Question 2
“Are models constructed to assess the long-term (≥15 
years or lifetime) risk of a first CVD event in adults 
effective in assessing variation in long-term risk among 
adults at low or intermediate short-term risk, whether 
analyzed separately or in combination?”
Younger men (typically <50 years of age) and most women 
have low (eg, <5% or <10%) predicted 10-year risks of CHD 
and more broad CVD outcomes, even in the presence of sig-
nificant risk factor burden.45,46 However, extensive epidemio-
logical, pathological, and basic science data indicate that the 
development of atherosclerosis, the precursor of ASCVD, 
occurs over decades and is related to long-term and cumula-
tive exposure to causal, modifiable risk factors. Thus, a life-
course perspective on risk assessment and prevention must 
be taken, especially among younger individuals. The primary 
value of risk factor measurement and quantitative long-term 
risk estimation in younger adults is 2-fold: first, to identify risk 
in individuals with extreme values of risk factors (eg, familial 
hypercholesterolemia); and second, to provide risk informa-
tion and context for the potential benefits of lifestyle modifi-
cation. When posing CQ2, the Work Group did not anticipate 
that long-term or lifetime risk would replace 10-year risk 
assessment as the foundation for absolute risk assessment and 
clinical decision making. Rather, longer-term risk estimates, 
if found to be useful, could provide adjunctive information for 
risk communication.
CQ2 was developed to assess the utility of long-term and 
lifetime risk assessment as an adjunct to short-term (10-year) 
risk assessment. It was recognized that there is little “discon-
nect” with regard to approaches to prevention when the 10-year 
risk estimate is high (eg, >10% predicted 10-year risk); such 
patients merit intensive prevention efforts and should be con-
sidered for drug therapy to reduce or modify adverse levels of 
causal risk factors. CQ2 was selected for evaluation to deter-
mine whether quantitative or semiquantitative long-term risk 
assessment would provide differential information that could 
be useful in risk communication, specifically to patients esti-
mated to be at lower short-term risk. However, it is unclear 
what the long-term predicted and observed risks for CHD and 
CVD are among individuals who are at low predicted 10-year 
risk. CQ2 was designed to identify studies that assessed both 
short- and long-term risk, focusing in particular on those stud-
ies that provide long-term outcomes data for groups predicted 
to be at low 10-year risk. If a sufficiently large proportion of 
the population is at high long-term risk despite being at low 
short-term risk, then incorporating long-term risk assessment 
Table 6. Expert Opinion Thresholds for Use of Optional 
Screening Tests When Risk-Based Decisions About Initiation 
of Pharmacological Therapy Are Uncertain After Quantitative 
Risk Assessment
Measure
Support Revising  
Risk Assessment  
Upward
Do Not Support  
Revising Risk  
Assessment
Family history  
  of premature  
CVD
Male <55 years of age
  Female <65 years of age
 (first-degree relative)
Occurrences at older  
 ages only (if any)
hs-CRP ≥2 mg/L <2 mg/L
CAC score ≥300 Agatston units or  
  ≥75th percentile for age, 
sex, and ethnicity*
<300 Agatston units and  
  <75th percentile for age, 
sex, and ethnicity*
ABI <0.9 ≥0.9
*For additional information, see http://www.mesa-nhlbi.org/CACReference.aspx.
ABI indicates ankle-brachial index; CAC, coronary artery calcium; CVD, 
cardiovascular disease; and hs-CRP, high-sensitivity C-reactive protein.
†Based on new evidence reviewed during ACC/AHA update of the 
evidence.
 by guest on A
pril 2, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
Goff et al  2013 ACC/AHA Cardiovascular Risk Assessment Guideline  S59
into routine clinical practice might have value for informing 
risk discussions with patients and guiding therapeutic lifestyle 
counseling and other aspects of care.
6.2.1. Summary of Evidence for CQ2
Ten studies that met inclusion/exclusion criteria were identi-
fied by the systematic review performed in April 2011 and were 
examined.19–22,47–52 Publication dates ranged from 1999 to 2009. 
All of the studies were observational. On the basis of these stud-
ies, 7 evidence statements were adopted (Appendix 5).
Multiple sources provided consistent evidence for the asso-
ciations of traditional risk factors with events occurring during 
both short-term and long-term follow-up. The important asso-
ciations are best represented and understood in the context 
of multivariable risk equations that reliably predict absolute 
risk of ASCVD events. In addition, most of these risk factors 
are both causal and modifiable, which indicates their central 
clinical importance for ASCVD prevention efforts. Given the 
additional evidence suggesting improved risk prediction with 
updated clinical covariates, the Work Group makes the follow-
ing recommendations.
6.2.2. Recommendations for CQ2: Long-Term Risk 
Assessment
Recommendation 1. It is reasonable to assess traditional 
ASCVD risk factors‡ every 4 to 6 years in adults 20 to 79 
years of age who are free from ASCVD and to estimate 10-year 
ASCVD risk every 4 to 6 years in adults 40 to 79 years of age 
who are free from ASCVD.
NHLBI Grade: B (Moderate); ACC/AHA COR: IIa, LOE: B
Recommendation 2. Assessment of 30-year or lifetime 
ASCVD risk on the basis of traditional risk factors‡ may be 
considered in adults 20 to 59 years of age who are free from 
ASCVD and are not at high short-term risk.
NHLBI Grade: C (Weak); ACC/AHA COR: IIb, LOE: C
A Web-based application enabling estimation of 10-year and life-
time risk of ASCVD is available at http://my.americanheart.org/
cvriskcalculator and http://www.cardiosource.org/en/Science-
And-Quality/Practice-Guidelines-and-Quality-Standards/2013-
Prevention-Guideline-Tools.aspx.
Evidence was not found on the utility of lifetime risk assess-
ment for guiding pharmacological therapy decisions, and the 
Work Group judged that long-term and lifetime risk informa-
tion may be used more appropriately at this time to motivate 
therapeutic lifestyle change in younger individuals. This per-
spective influenced the choice of age 20 years as the starting 
point for long-term risk assessment, despite a threshold of age 
40 years for short-term 10-year ASCVD risk assessment.
Long-term and lifetime risk estimation may be less valu-
able for individuals who are found to be at high short-term 
(10-year) risk according to multivariable equations, for whom 
decisions about prevention efforts may be clear. However, 
an understanding of long-term risk may provide a means of 
encouraging adherence to lifestyle or pharmacological thera-
pies, especially for patients who might have difficulty under-
standing the importance of their short-term risk. Likewise, for 
older individuals or those with limited life expectancy, clinical 
considerations should dictate the intensity of risk assessment 
and prevention efforts.
7. Implementation Considerations 
for Risk Assessment
A suggested approach for incorporating these recommenda-
tions into clinical practice is shown in Figure 1. For patients 
20 to 79 years of age who are free from clinical ASCVD, the 
first step is to assess ASCVD risk factors. Although it is reason-
able to assess ASCVD risk factors in individuals younger or 
older than this age range, limitations of available data prevented 
the development of robust risk assessment algorithms in those 
populations. Hence, for patients outside this age range, provid-
ers should refer to applicable clinical practice guidelines (ie, 
pediatric53 and adult primary prevention guidelines.44,54,56 Risk 
assessment should be repeated every 4 to 6 years in persons 
who are found to be at low 10-year risk (<7.5%). Beginning at 
age 40 years, formal estimation of the absolute 10-year risk of 
ASCVD is recommended.20,21 Long-term or lifetime risk esti-
mation is recommended for all persons who are between 20 
and 39 years of age and for those between 40 and 59 years of 
age who are determined to be at low 10-year risk (<7.5%). As 
shown in Figure 1, all patients should receive applicable risk 
information and appropriate lifestyle counseling. The 10-year 
risk estimates provided by the new Pooled Cohort Equations 
differ from those generated by the Adult Treatment Panel III 
algorithm in several respects,24 as discussed in detail in the 
Full Work Group Report supplement. To summarize, on the 
basis of the risk estimation algorithm recommended by Adult 
Treatment Panel III, approximately 31.9% of the ASCVD-free, 
nonpregnant US population between 40 and 79 years of age 
have a 10-year risk of a first hard CHD event of at least 10% or 
have diabetes. On the basis of the new Pooled Cohort Equations 
described here, approximately 32.9% have a 10-year risk of a 
first hard ASCVD of at least 7.5%. The outcomes and thresh-
olds of these 2 approaches are different, but the overlap of these 
2 means of defining high-risk groups is substantial, at roughly 
75%. Nonetheless, these important differences make simple lin-
ear conversions imprecise. We recommend that healthcare orga-
nizations convert to these new Pooled Cohort Equations as soon 
as practical (Appendix 7). A Web-based application enabling 
estimation of 10-year and lifetime risk of ASCVD is available at 
http://my.americanheart.org/cvriskcalculator and http://www.
cardiosource.org/en/Science-And-Quality/Practice-Guidelines-
and-Quality-Standards/2013-Prevention-Guideline-Tools.aspx.
8. Evidence Gaps and Future Research Needs
The Work Group strongly recommends continued research to 
fill gaps in knowledge about short- and long-term ASCVD risk 
assessment and outcomes in all racial/ethnic groups, across 
the age spectrum, and in women and men. Future research 
should include analyses of short- and long-term risk in diverse 
groups, optimal communication of ASCVD risk information, 
utility of short-and long-term risk assessment for motivating 
behavioral change and adherence to therapy, utility of short-
and long-term risk assessment for influencing risk factor lev-
els and clinical outcomes, utility of differential information 
‡Age, sex, total cholesterol, high-density lipoprotein cholesterol, 
systolic BP, use of antihypertensive therapy, diabetes, and current smoking.
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conveyed by short- and long-term risk assessment, and utility 
of novel risk markers in short- and long-term risk assessment.
9. Conclusions
The Work Group’s approach to risk assessment represents a 
step forward in ASCVD prevention that is large enough to jus-
tify the challenges inherent in implementing a new approach, 
rather than staying with the CHD risk assessment approach 
recommended previously. The final recommendations are sum-
marized in Table 4 and Figure 1. Two major advantages of this 
approach are the ability to estimate risk for a broader-based 
ASCVD outcome that is more relevant to additional segments 
of the population, including women and African Americans, 
and the ability to provide risk estimates specific to African 
Americans. Promotion of lifetime risk estimation may repre-
sent an additional step forward in supporting lifestyle behavior 
change counseling efforts. Periodic updates of the guidelines 
should address numerous issues related to risk assessment.
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table are modest unless otherwise noted.
*Significant relationship.
ACC indicates American College of Cardiology; AHA, American Heart Association; and NHLBI, National Heart, Lung, and Blood Institute.
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Appendix 2. Expert Reviewer Relationships With Industry and Other Entities—2013 ACC/AHA Guideline on Assessment of 
Cardiovascular Risk
Reviewer Employment Representing Consultant
Speaker’s 
Bureau
Ownership/ 
Partnership/ 
Principal
Personal  
Research
Expert  
Witness
Ezra A.  
Amsterdam
University of California (Davis) 
Medical Center, Division of 
Cardiology—Professor
ACC/AHA None None None None None
Ralph G.  
Brindis
University of California, San 
Francisco—Department of 
Medicine & the Phillip R. Lee 
Institute for Health Policy 
Studies—Clinical Professor  
of Medicine
ACC/AHA  
Task Force  
on Practice 
Guidelines
None None None None None
Frederick A. 
Masoudi
University of Colorado,
Anschutz Medical Campus—
Professor of Medicine 
(Cardiology)
ACC/AHA None None None None None
This table represents the relationships of reviewers with industry and other entities that were self-disclosed at the time of peer review. It does not necessarily reflect 
relationships with industry at the time of publication. To review the NHLBI and ACC/AHA’s current comprehensive policies for managing relationships with industry 
and other entities, please refer to http://www.nhlbi.nih.gov/guidelines/cvd_adult/coi-rwi_policy.htm and http://www.cardiosource.org/Science-And-Quality/Practice-
Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx.
ACC indicates American College of Cardiology; and AHA, American Heart Association.
Appendix 3. Abbreviations
ABI = ankle-brachial index
ApoB = apolipoprotein B
ASCVD = atherosclerotic cardiovascular disease
BP = blood pressure
CAC = coronary artery calcium
CHD = coronary heart disease
CIMT = carotid intima-media thickness
COR = Class of Recommendation
CQ = critical question
CVD = cardiovascular disease
hs-CRP = high-sensitivity C-reactive protein
LOE = Level of Evidence
NHLBI = National Heart, Lung, and Blood Institute
RWI = relationships of authors with industry and other entities
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Appendix 4. Evidence Statements for CQ1
Evidence 
Statement 
Number Author/Group Factor Evidence Statement/Conclusion
1 USPSTF9 hs-CRP “Strong evidence indicates that CRP is associated with CHD events. Moderate, consistent evidence  
suggests that adding CRP to risk prediction models among initially intermediate-risk persons  
improves risk stratification.”
“Few studies directly assessed the effect of CRP on risk reclassification in intermediate-risk persons.”
hs-CRP was associated with risk, and its use resulted in some reclassification in intermediate-risk persons,  
but it was not clear whether this reclassification led to a net improvement in prediction. Values of receiver 
operating curve C-statistics (measures of discrimination) are mentioned but not reported; hence, no evidence 
on discrimination, calibration, net reclassification index, or cost-effectiveness was provided.
Reports some impact on reclassification, probably modest (pp. 488–491).
2 Helfand et al, 
200912
hs-CRP, CAC, 
CIMT, ABI
With regard to risk assessment for major CHD, the authors concluded that, “The current evidence does not 
support the routine use of any of the 9 risk factors for further risk stratification of intermediate-risk persons.” 
The 9 risk factors examined were: hs-CRP, CAC score as measured by electron-beam computed  
tomography, lipoprotein (a) level, homocysteine level, leukocyte count, fasting blood glucose, periodontal 
disease, ABI, and CIMT.
hs-CRP was associated with CHD and led to some reclassification. The authors cite the JUPITER results to  
support the conclusion that hs-CRP testing may be useful in intermediate-risk patients to drive statin therapy. 
The Work Group recognizes that more recent individual study results have been published.  
Updated systematic reviews addressing discrimination, calibration, reclassification, and cost issues in the 
context of the newer ASCVD risk assessment model proposed in the present document are needed.
CAC was associated with CHD and with some reclassification, but the size and value of this reclassification  
are uncertain. The document provides little evidence with regard to discrimination, calibration, and cost-
effectiveness. The Work Group also is concerned about radiation and incidental findings. The Work Group 
recognizes that more recent individual study results have been published. Updated systematic reviews 
addressing discrimination, calibration, reclassification, cost, and safety issues in the context of the newer  
ASCVD risk assessment model proposed in the present document are needed.
CIMT was associated with CHD, but the document provides little evidence for reclassification, discrimination,  
calibration, and cost-effectiveness. The Work Group also has concerns about measurement issues. 
Standardization of CIMT measurement is a major challenge. The Work Group recognizes that more recent 
individual study results have been published. Updated systematic reviews addressing discrimination, 
calibration, reclassification, cost, and measurement (standardization) issues in the context of the newer  
ASCVD risk assessment model proposed in this document are needed.
ABI was associated with CHD and some reclassification, but the size and value of this reclassification are  
uncertain. Evidence suggests some improvement in discrimination, but the document provides little evidence 
with regard to calibration and cost-effectiveness. The Work Group members are uncertain whether more 
recent individual study results have been published relevant to ABI. Updated systematic reviews addressing 
discrimination, calibration, reclassification, and cost issues in the context of the newer ASCVD risk 
assessment model proposed in this document are needed.
3 Emerging Risk 
Factors 
Collaboration13
hs-CRP “CRP concentration has continuous associations with the risk for coronary heart disease, ischaemic stroke, 
vascular mortality, and death from several cancers and lung disease that are each of broadly similar size. 
The relevance of CRP to such a range of disorders is unclear. Associations with ischaemic vascular disease 
depend considerably on conventional risk factors and other markers of inflammation.”
hs-CRP is associated with risk of CVD. This analysis did not directly assess value in risk prediction. No  
additional evidence was provided for discrimination, calibration, reclassification, or cost-effectiveness.
4 Schnell-Inderst  
et al, 201017
hs-CRP For MI and cardiovascular mortality, “Adding hs-CRP to traditional risk factors improves risk prediction, but the 
clinical relevance and cost-effectiveness of this improvement remain unclear.”
Absolute differences in C-statistics between models including and not including hs-CRP ranged from  
0.00 to 0.027.
Some evidence was provided to support the cost-effectiveness of hs-CRP testing in some modeling  
scenarios, characterized by intermediate- and higher-risk populations and lower-cost (generic) statins  
of at least moderate efficacy.
5 Emerging Risk 
Factors 
Collaboration40
ApoB This article provided evidence of rough equivalence of associations of CVD with non–HDL-C and ApoB  
after multivariable adjustment (including HDL-C). See Figure 1 for CHD and the text for stroke.  
By inference, this finding means there would be rough equivalence between ApoB and total cholesterol  
with similar adjustment.
(Continued)
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Appendix 4. Continued
Evidence 
Statement 
Number Author/Group Factor Evidence Statement/Conclusion
6 Sniderman  
et al, 201142
ApoB ApoB was more strongly related to risk of ASCVD than either non–HDL-C or LDL-C in a substitution model 
that also included HDL-C. No evidence was presented pertinent to an addition model in which ApoB 
might be added to a model that included total cholesterol, LDL-C, or non–HDL-C. Additional models are 
the type of model of interest to this question. By inference, these results maymean that ApoB is more 
strongly related to risk than is total cholesterol. This article did not address directly the value of adding 
ApoB to a model with traditional risk factors. No information was presented for discrimination, calibration, 
reclassification, or cost. The relative risks evaluated in the meta-analysis were adjusted for various sets of 
covariates in the various primary reports, and the adjustments were judged to be incomplete. Furthermore, 
studies of varying designs and quality were included, leaving the Work Group members concerned about 
the validity of the evidence.
7 Kodama et al, 
200941
Cardiorespiratory 
fitness
Better cardiorespiratory fitness was associated with lower risk of all-cause mortality and CHD/CVD.  
According to the sensitivity analyses in Table 2, evidence of association was weaker for CHD/CVD, but 
still significant, when based on studies with more complete adjustment for other risk factors. The utility 
of assessing cardiorespiratory fitness in risk prediction was not assessed (discrimination, calibration, 
reclassification, and cost).
8 Ankle Brachial 
Index 
Collaboration11
ABI ABI is associated with total CHD risk and leads to significant reclassification, and the pattern of reclassification 
is different by sex. Among men, the effect is to down-classify high-risk men. Among women, the effect is 
to up-classify low-risk women. Overall, the FRS, as applied by the investigators, showed relatively poor 
discrimination in this meta-analysis, with C-statistics of 0.646 (95% CI: 0.643–0.657) in men and 0.605 
(0.590–0.619) in women. There was an improvement in C-statistic in both men (0.655 [0.643–0.666]) and 
women (0.658 [0.644–0.672]) when ABI was added to a model with FRS. The improvement in the C-statistic 
was greater and significant in women but was not significant in men. No evidence on calibration, net 
reclassification index, or cost-effectiveness was provided.
9 Empana et al, 
201110
Family history of 
CHD
“In separate models adjusted for age, gender, and study cohort, a family history of CHD, BMI, and waist 
circumference were all predictors of CHD. When traditional risk factors were controlled for, family history 
of CHD (P<0.001) and BMI (P=0.03) but not waist circumference (P=0.42) remained associated with CHD. 
However, the addition of family history of CHD or BMI to the traditional risk factors model did not improve 
the discrimination of the model (not shown).”
This article developed a CHD risk prediction algorithm based on 4 French population studies and 
evaluated, among other factors, the contribution of family history to traditional risk factors. Family 
history of CHD was defined as the self-report of a MI in first-degree relatives (parents and siblings) in the 
D.E.S.I.R. and SU.VI.MAX studies, as a history of MI before age 55 years in men and before age 65 years 
in women in parents, siblings, and grandparents in the PRIME study, and as a death due to MI in first-
degree relatives in the Three City study. No evidence on calibration, net reclassification index, or cost-
effectiveness was provided.
10 Moyer et al, 
201315
ABI This article is an updated review of the utility of assessing ABI for the USPSTF.
“The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms 
of screening for PAD and CVD risk assessment with the ABI in adults. (I statement)”
“The USPSTF found no evidence that screening for and treatment of PAD in asymptomatic patients leads to 
clinically important benefits. It also reviewed the potential benefits of adding the ABI to the FRS and found 
evidence that this results in some patient risk reclassification; however, how often the reclassification is 
appropriate or whether it results in improved clinical outcomes is not known.”
The Work Group notes that this review provides some evidence that assessing ABI may improve risk 
assessment; however, no evidence was found by the USPSTF reviewers pertinent to the question of whether 
measuring ABI leads to better patient outcomes.
(Continued)
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Appendix 4. Continued
Evidence 
Statement 
Number Author/Group Factor Evidence Statement/Conclusion
11. Peters et al,  
201216
CIMT, CAC This article is a systematic review of the literature on the contribution to risk assessment of imaging for 
subclinical atherosclerosis.
“Published evidence on the added value of atherosclerosis imaging varies across the different markers, with 
limited evidence for FMD and considerable evidence for CIMT, carotid plaque and CAC. The added predictive 
value of additional screening may be primarily found in asymptomatic individuals at intermediate cardiovascular 
risk. Additional research in asymptomatic individuals is needed to quantify the cost-effectiveness and impact of 
imaging for subclinical atherosclerosis on cardiovascular risk factor management and patient outcomes.”
With regard to CIMT:
“The c-statistic of the prediction models without CIMT increased from 0.00 to 0.03 when CIMT was added. In 
the Atherosclerosis Risk In Communities (ARIC) study, addition of CIMT to the prediction model resulted in an NRI 
overall of 7.1% (95% CI 2.2% to 10.6%) and an IDI of 0.007 (95% CI 0.004 to 0.010). The NRI intermediate was 
16.7% (95% CI 9.3% to 22.4%). In contrast, 10 year results from the Carotid Atherosclerosis Progression Study 
showed that addition of CIMT to the prediction model resulted in an IDI of 0.04% and NRI overall of –1.41%. 
Analysis of 1,574 participants from the Firefighters and Their Endothelium study showed an NRI overall of 11.6% 
(P=0.044) and an NRI intermediate of 18.0% (P=0.034).”
The Work Group notes that this article provides some evidence to consider assessing CIMT; however, this 
conclusion was not supported by the article by Den Ruijter et al described below.18
With regard to CAC:
“The c-statistic increased from 0.04 to 0.13 when CAC was added to the model. Four recently published 
studies also reported results on the NRI and/or the IDI. One of these studies comprised a subgroup analysis of 
an earlier publication in the total population in individuals without indications for statin therapy. Analyses of 
the MESA study showed that addition of CAC to the conventional prediction model resulted in an NRI overall 
of 25% (95% CI 16% to 34%) and an NRI intermediate of 55% (95% CI 41% to 69%). The IDI in the MESA 
study was 0.026. Results were similar in the Rotterdam study. Addition of CAC to the prediction model led 
to an NRI overall of 14% (P<0.01) which was mainly driven by correctly reclassifying those at intermediate 
risk according to the traditional prediction model. Results from the Heinz Nixdorf Recall study also showed 
large NRIs when CAC was added to the Framingham Risk Score. Using different thresholds to define the 
intermediate risk category (10%–20% or 6%–20%), the NRI overall was 22% and 20%, respectively. The 
NRI intermediate was 22% for intermediate risk thresholds of 10%–20% and 31% for intermediate risk 
thresholds of 6%–20%. In addition, the IDI was 0.0152 when the prediction models with and without CAC 
were compared. The NRI overall was 25.1% and the IDI was 0.0167 in individuals from the Heinz Nixdorf 
Recall study without indications for statin therapy.” The Work Group notes that this article provides evidence 
to support the conclusion that assessing CAC is likely to be the most useful approach to improving risk 
assessment among individuals found to be at intermediate risk after formal risk assessment. Furthermore, 
we note that the outcomes in the studies reviewed above were CHD, not ASCVD. The Work Group discussed 
concerns about cost, radiation exposure, and the uncertainty of the contribution of assessing CAC to 
estimation of 10-year risk of hard ASCVD after formal risk assessment.
12. Kashani et al, 
201314
Family  
history
This article is an integrative literature review on the contribution of assessing family history to risk appraisal.
“The evidence demonstrates that family history is an independent contributor to risk appraisal and 
unequivocally supports its incorporation to improve accuracy in global CVD risk estimation.”
The Work Group notes that a variety of endpoints, clinical and subclinical, were included in the reviewed articles. 
No evidence on discrimination, calibration, net reclassification index, or cost-effectiveness was provided.
13. Den Ruijter et al, 
201218
CIMT This article is an individual-level meta-analysis of “14 population-based cohorts contributing data for 45 828 
individuals. During a median follow-up of 11 years, 4007 first-time MIs or strokes occurred.”
“We first refitted the risk factors of the FRS and then extended the model with common CIMT measurements 
to estimate the absolute 10-year risks to develop a first-time MI or stroke in both models. The C-statistic 
of both models was similar (0.757; 95% CI, 0.749–0.764; and 0.759; 95% CI, 0.752–0.766). The net 
reclassification improvement with the addition of common CIMT was small (0.8%; 95% CI, 0.1%–1.6%). In 
those at intermediate risk, the net reclassification improvement was 3.6% in all individuals (95% CI, 2.7%–
4.6%) and no differences between men and women.”
“The addition of common CIMT measurements to the FRS was associated with small improvement in 10-year 
risk prediction of first-time MI or stroke, but this improvement is unlikely to be of clinical importance.”
The Work Group judged this article to provide the strongest evidence available on the potential value of CIMT 
to risk assessment. The Work Group also has concerns about measurement issues. Standardization of CIMT 
measurement is a major challenge.
ABI indicates ankle-brachial index; ApoB, apolipoprotein B; BMI, body mass index; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CHD, 
coronary heart disease; CI, confidence interval; CIMT, carotid intima-media thickness; CRP, C-reactive protein; CVD, cardiovascular disease; FMD, flow-mediated dilation; 
FRS, Framingham Risk Score; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; IDI, integrative discrimination index; JUPITER, 
Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin; LDL-C, low-density lipoprotein cholesterol; MESA, Multi-Ethnic 
Study of Atherosclerosis; NRI, net reclassification index; PAD, peripheral artery disease; MI, myocardial infarction; and USPSTF, US Preventive Services Task Force.
 by guest on A
pril 2, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
Goff et al  2013 ACC/AHA Cardiovascular Risk Assessment Guideline  S69
Appendix 5. Evidence Statements for CQ2
Evidence  
Statement  
Number Evidence Statement References
1. We found no evidence assessing variations in long-term or lifetime risk of CVD outcomes among persons at low or 
intermediate short-term risk in racial/ethnic groups other than non-Hispanic whites in the United States and Europe.
Strength of Evidence: None
—
2. ASCVD risk factors measured in young and middle-aged adults, considered singly or jointly, generally are associated 
with short-term (≤10 years), long-term (≥15 years), and lifetime risk of ASCVD.
Strength of Evidence: Low (for diabetes and metabolic syndrome) to Moderate (for BMI, cholesterol, systolic BP,  
and smoking).
20,21,47,48,51,52
3. Multivariable short-term (10-year) CHD risk prediction models underestimate absolute lifetime risk of CHD but 
maystratify relative lifetime risk of CHD in women and older men.*
Strength of Evidence: Low
*CHD is defined as all manifestations of CHD, or as CHD death/nonfatal MI.
22
4. Long-term (30-year) risk equations based on traditional ASCVD risk factors* provide more accurate prediction of long-
term ASCVD† risk than do extrapolations of short-term (10-year) risk equations among individuals 20–59 years of age 
who are free from ASCVD.
Strength of Evidence: Low
*Age, sex, total cholesterol, HDL-C, systolic BP, use of antihypertensive therapy, diabetes, and current smoking.
†CHD death, nonfatal MI, or fatal/nonfatal stroke; or all ASCVD.
20
5. The presence and severity of selected traditional ASCVD risk factors* stratify absolute levels of lifetime risk of ASCVD† 
among non-Hispanic white adults 45–50 years of age who are free of ASCVD and not at high short-term risk.
Strength of Evidence: Low
*Risk factors were considered in 5 mutually exclusive strata encompassing the full spectrum of risk levels, as follows: 
1) ≥2 major risk factors (defined as total cholesterol ≥240 mg/dL or treated, systolic BP ≥160 or diastolic BP  
≥100 mm Hg or treated, or diabetes, or current smoking) and lifetime risk of ASCVD >50%; 2) only 1 major risk 
factor and lifetime risk of ASCVD 39%–50%; 3) ≥1 elevated risk factor (defined as untreated total cholesterol 200 to 
239 mg/dL, or untreated systolic BP 140–159 mm Hg or diastolic BP 90–99 mm Hg, and no diabetes and no current 
smoking) and lifetime risk of ASCVD 39%–46%; 4) ≥1 risk factor at nonoptimal levels (untreated total cholesterol 
180–199 mg/dL, or untreated systolic BP 120–139 mm Hg or diastolic BP 80–89 mm Hg, and no diabetes and no 
current smoking) and lifetime risk of ASCVD 27%–36%; and 5) all optimal levels of risk factors (defined as untreated 
total cholesterol <180 mg/dL, and untreated BP <120/<80 mm Hg, and no diabetes, and no current smoking) and 
lifetime risk of ASCVD <10%.
†CHD death, MI, coronary insufficiency, angina, fatal/nonfatal atherothrombotic stroke, claudication, other CVD death.
21
6. Long-term (≥15 years) risk prediction models based on selected traditional ASCVD risk factors* predict CHD death with 
good discrimination and calibration, and better in women than men, in US non-Hispanic white populations.
Strength of Evidence: Low
*Age, sex, total cholesterol, systolic BP, diabetes, and smoking.
50
7. Measuring and updating ASCVD risk factors every 4–6 years improves short- and long-term risk prediction.
Strength of Evidence: Moderate
19,20
ASCVD indicates atherosclerotic cardiovascular disease; BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; CQ, critical question; CVD, 
cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; MI, myocardial infarction; and —, none.
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Appendix 7. Development and Steps for Implementation of the 
ASCVD Pooled Cohort Risk Equations
Prior experience with the development of the Framingham 
Heart Study 10-year CHD risk prediction equations24,57 and 
the more recent Framingham 10-year general CVD risk pre-
diction equations,58 was used as a basis for developing the 
new Pooled Cohort Risk Equations. To expand the utility and 
generalizability of the new equations, extensive data were 
used from several large, racially and geographically diverse, 
modern NHLBI-sponsored cohort studies, including the ARIC 
(Atherosclerosis Risk in Communities) study,8 Cardiovascular 
Health Study,5 and the CARDIA (Coronary Artery Risk 
Development in Young Adults) study,7 combined with appli-
cable data from the Framingham Original and Offspring Study 
cohorts.4,6
A total of 11 240 white women (who experienced 902 hard 
ASCVD events), 9098 white men (1259 hard ASCVD events), 
2641 African-American women (290 hard ASCVD events), 
and 1647 African-American men (238 hard ASCVD events) 
who met the following criteria were included: 40 to 79 years 
of age, apparently healthy, and free of a previous history of 
nonfatal myocardial infarction (recognized or unrecognized), 
stroke, heart failure, percutaneous coronary intervention, coro-
nary artery bypass surgery, or atrial fibrillation. Data from the 
included participants were used to develop sex- and race-spe-
cific equations to predict 10-year risk of a first hard ASCVD 
event. Because of the growing health burden of heart failure, the 
Work Group examined the possibility of including heart fail-
ure as an outcome. However, study-by-study ascertainment and 
adjudication of heart failure varied considerably, and therefore 
heart failure could not be included as an outcome. Because of 
known substantial geographic variation in use (Dartmouth Atlas 
of Healthcare, http://www.dartmouthatlas.org/), self-selection, 
and physician recommendation biases,64 coronary revascular-
ization was also not included as an endpoint.
The Pooled Cohort Equations for estimating ASCVD were 
developed from sex- and race-specific proportional-hazards 
models that included the covariates of age, treated or untreated 
systolic BP level, total cholesterol and high-density lipoprotein 
cholesterol levels, current smoking status (yes/no), and history 
of diabetes (yes/no). A variable representing lipid treatment 
was considered but not retained in the final model because 
lipid therapy was relatively uncommon in the cohorts and sta-
tistical significance was lacking. Baseline characteristics of 
the participants included in the equation derivation model are 
shown in the Full Work Group Report Data supplement, as are 
details of the methods used to derive, evaluate, and validate 
(internally and externally) the resulting risk equations and their 
potential limitations. In summary, discrimination and calibra-
tion of the models were very good. C-statistics ranged from 
a low of 0.713 (African-American men) to a high of 0.818 
(African-American women). Calibration chi-square statistics 
ranged from a low of 4.86 (non-Hispanic white men) to a high 
of 7.25 (African-American women). The coefficients for the 
equations for calculating an estimate of an individual’s 10-year 
risk of a first hard ASCVD event are provided in Table A, along 
with examples based on a specific risk profile for each race–sex 
group. The step-by-step process for estimating the risk in the 
specific examples of Table A is provided in Table B. These 2 
tables are intended to enable programmers to integrate these 
equations into electronic health records.
The Work Group also considered the inclusion of additional 
and novel risk markers in the risk equations. On the basis of 
the availability of data across cohorts at applicable examina-
tion cycles, additional risk markers were evaluated for poten-
tial inclusion if they improved model performance within 
the framework of Hlatky et al.39 The additional risk markers 
that were evaluated included diastolic BP, family history of 
ASCVD, moderate or severe chronic kidney disease (defined 
as an estimated glomerular filtration rate of <60 mL/min per 
1.73 m2),65 and body mass index (continuous or categorical). 
None of these variables significantly improved discrimination 
for 10-year hard ASCVD risk prediction when added to the 
final base models. Other risk markers (hs-CRP, ApoB, micro-
albuminuria, cardiorespiratory fitness, CAC score, CIMT, 
and ABI) could not be evaluated in creating this new model 
because of absence of data or lack of inclusion in the appropri-
ate examination cycle of 1 or more of the studies. Therefore, 
these and the other risk markers were addressed in CQ1 as 
potential adjuncts to quantitative risk estimation.
Further research using state-of-the art statistical techniques 
(including net reclassification improvement and integrative 
discrimination index66) is needed to examine the utility of 
novel biomarkers when added to these new Pooled Cohort 
Equations in different populations and patient subgroups. 
Randomized clinical trials demonstrating the utility of screen-
ing with novel risk markers would represent the best evidence 
for their inclusion in future risk assessment algorithms. In the 
absence of evidence from trials, methodologically rigorous 
observational studies should be conducted to evaluate utility.
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Table A. Equation Parameters of the Pooled Cohort Equations for Estimation of 10-Year Risk of Hard ASCVD* and Specific Examples 
for Each Race and Sex Group
White African American
Coefficient
Individual Example
Value
Coefficient
× Value† Coefficient
Individual Example
Value
Coefficient
× Value†
Women (Example: 55 years of age with total cholesterol 213 mg/dL, HDL-C 50 mg/dL, untreated systolic BP 120 mm Hg, nonsmoker, and without diabetes)
Ln Age (y) –29.799 4.01 –119.41 17.114 4.01 68.58
Ln Age, Squared 4.884 16.06 78.44 N/A N/A N/A
Ln Total Cholesterol (mg/dL) 13.540 5.36 72.59 0.940 5.36 5.04
Ln Age × Ln Total Cholesterol –3.114 21.48 –66.91 N/A N/A N/A
Ln HDL-C (mg/dL) –13.578 3.91 –53.12 –18.920 3.91 –74.01
Ln Age × Ln HDL-C 3.149 15.68 49.37 4.475 15.68 70.15
Ln Treated Systolic BP (mm Hg) 2.019 — — 29.291 — —
Ln Age × Ln Treated Systolic BP N/A N/A N/A –6.432 — —
Ln Untreated Systolic BP (mm Hg) 1.957 4.79 9.37 27.820 4.79 133.19
Ln Age × Ln Untreated Systolic BP N/A N/A N/A –6.087 19.19 –116.79
Current Smoker (1=Yes, 0=No) 7.574 0 0 0.691 0 0
Ln Age × Current Smoker –1.665 0 0 N/A N/A N/A
Diabetes (1=Yes, 0=No) 0.661 0 0 0.874 0 0
Individual Sum –29.67 86.16
Mean (Coefficient × Value) N/A N/A –29.18 N/A N/A 86.61
Baseline Survival N/A N/A 0.9665 N/A N/A 0.9533
Estimated 10-y Risk of Hard ASCVD N/A N/A 2.1% N/A N/A 3.0%
Men (Example: 55 years of age with total cholesterol 213 mg/dL, HDL-C 50 mg/dL, untreated systolic BP 120 mm Hg, nonsmoker, and without diabetes)
Ln Age (y) 12.344 4.01 49.47 2.469 4.01 9.89
Ln Total Cholesterol (mg/dL) 11.853 5.36 63.55 0.302 5.36 1.62
Ln Age × Ln Total Cholesterol –2.664 21.48 –57.24 N/A N/A N/A
Ln HDL-C (mg/dL) –7.990 3.91 –31.26 –0.307 3.91 –1.20
Ln Age × Ln HDL-C 1.769 15.68 27.73 N/A N/A N/A
Ln Treated Systolic BP (mm Hg) 1.797 — — 1.916 — —
Ln Untreated Systolic BP (mm Hg) 1.764 4.79 8.45 1.809 4.79 8.66
Current Smoker (1=Yes, 0=No) 7.837 0 0 0.549 0 0
Ln Age × Current Smoker –1.795 0 0 N/A N/A N/A
Diabetes (1=Yes, 0=No) 0.658 0 0 0.645 0 0
Individual Sum 60.69 18.97
Mean (Coefficient × Value) N/A N/A 61.18 N/A N/A 19.54
Baseline Survival N/A N/A 0.9144 N/A N/A 0.8954
Estimated 10-y Risk of Hard ASCVD N/A N/A 5.3% N/A N/A 6.1%
*Defined as first occurrence of nonfatal myocardial infarction or CHD death, or fatal or nonfatal stroke.
†Coefficient × Value: For age, lipids, and BP, defined as the natural log of the value multiplied by the parameter estimate. When an age interaction is present with 
lipids or BP, the natural log of age is multiplied by the natural log of the lipid or BP, and the result is multiplied by the parameter estimate. N/A indicates that that specific 
covariate was not included in the model for that sex–race group; — indicates that this value was not included in the example (eg, this example used untreated systolic 
BP, not treated systolic BP).
ASCVD indicates atherosclerotic cardiovascular disease; BP indicates blood pressure; CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol; Ln, 
natural logarithm; and N/A, not included.
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Table B. Estimating an Individual’s 10-Year Risk of Incident Hard ASCVD
The hypothetical profile provided in Table 5 (the “Individual Example Value” column) is identical for each race and sex group and is based on the overall sample 
mean. The profile assumes an individual 55 years of age (for which the Ln[Age]=4.01), with a total cholesterol of 213 mg/dL, HDL-C of 50 mg/dL, and an untreated 
systolic BP of 120 mm Hg. This individual is not a current smoker and does not have diabetes. For the equations, the values for age, lipids, and systolic BP are Ln 
transformed. Interactions between age and lipids or age and systolic BP use the natural log of each variable (eg, Ln[Age]×Ln[Total Cholesterol]).
Calculation of the 10-year risk estimate for hard ASCVD can best be described as a series of steps. The natural log of age, total cholesterol, HDL-C, and systolic 
BP are first calculated with systolic BP being either a treated or untreated value. Any appropriate interaction terms are then calculated. These values are then 
multiplied by the coefficients from the equation (“Coefficient” column of Table A) for the specific race-sex group of the individual. The “Coefficient × Value” column 
in the table provides the results of the multiplication for the risk profile described above.
The sum of the “Coefficient × Value” column is then calculated for the individual. For the profile shown in Table A, this value is shown as “Individual Sum” for each 
race and sex group.
The estimated 10-year risk of a first hard ASCVD event is formally calculated as 1 minus the survival rate at 10 years (“Baseline Survival” in Table A), raised to the 
power of the exponent of the “Coefficient × Value” sum minus the race- and sex-specific overall mean “Coefficient × Value” sum; or, in equation form:
1 − S10
(lndX’B–MeanX’B)
Using white men as an example:
1 − 0.9144e(60.69–61.18)
equates to a 5.3% probability of a first hard ASCVD event within 10 years.
ASCVD indicates atherosclerotic cardiovascular disease; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; and Ln, natural logarithm.
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Correction
S74
In the article by Goff et al, “2013 ACC/AHA Guideline on the Assessment of Cardiovascular 
Risk: A Report of the American College of Cardiology/American Heart Association Task Force on 
Practice Guidelines,” which published online November 12, 2013, and appears in the supplement 
to the June 24, 2014, issue of the journal (Circulation. 2014;129[suppl 2]:S49–S73), several cor-
rections were needed.
These corrections have been made to the print version and to the current online version of the article, 
which is available at http://circ.ahajournals.org/lookup/doi/10.1161/01.cir.0000437741.48606.98.
1.  On the title page, the first footnote paragraph now reads, “This document was approved by the 
American College of Cardiology Board of Trustees, the American Heart Association Science 
Advisory and Coordinating Committee, and The Obesity Society Board of Trustees in November 
2013. The Academy of Nutrition and Dietetics affirms the value of this guideline.” The footnote 
previously did not refer to the Academy of Nutrition and Dietetics.
2.  On the title page, Robert A. Guyton, MD, FACC, was listed as a member of the ACC/AHA Task 
Force. His name has been removed from the list of Task Force members.
3.  Appendixes have been reordered and renumbered to maintain the journal style of publishing 
authors’ and peer reviewers’ RWI first as Appendix 1 and Appendix 2, respectively. Callouts in 
the text have been modified accordingly.
4.  Throughout the article, callouts to the “Full Work Group Report Supplement” have been hyper-
linked to the report.
5.  Throughout the article, the web-based calculator links have been updated to:
•  http://www.cardiosource.org/en/Science-And-Quality/Practice-Guidelines-and-Quality-
Standards/2013-Prevention-Guideline-Tools.aspx and
•  http://my.americanheart.org/cvriskcalculator
6. In Table 4,
•  The “Assessment of 10-Year Risk of a First Hard ASCVD Event” section, in the “NHLBI 
Evidence Statements” column, recommendation 2 read, “Appendix 2 CQ2/ES1.” It has been 
changed to read, “N/A.”
•  The header “CQ1: Use of Newer Risk Markers After Quantitative Risk Assessment” has 
been added after recommendation 2, and the header “CQ2: Long-Term Risk Assessment” 
has been added after recommendation 3.
7.  In Section 4, the last paragraph, a referral to the downloadable spreadsheet has been replaced 
with a referral to the web-based application sites http://my.americanheart.org/cvriskcalculator 
and http://www.cardiosource.org/en/Science-And-Quality/Practice-Guidelines-and-Quality-
Standards/2013-Prevention-Guideline-Tools.aspx.
8.  In Section 6.1.1, the last paragraph, the following text has been added: “….by Den Ruijter et al18 
reviewed during the ACC/AHA update period…”
9.  In Section 7,
•  Figure 1, a referral and reference number to the “Lifestyle Management (56)” guideline has 
been added in the 3 boxes on the right.
•  First paragraph, reference 56 has been added to the following sentence: “Hence, for patients 
outside this age range, providers should refer to applicable clinical practice guidelines (ie, 
pediatric53 and adult primary prevention guidelines44,54,56).”
•  First paragraph, references 20 and 21 have been added to the following sentence: 
“Beginning at age 40 years, formal estimation of the absolute 10-year risk of ASCVD is 
recommended.20,21”
(Circulation. 2014;129[suppl 2]:S74-S75.)
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Correction  S75
10.  After the references, “Key Words” have been added: “AHA Scientific Statements ◼ biomarkers 
◼ cardiovascular disease ◼ cholesterol ◼ primary prevention ◼ risk assessment ◼ risk reduc-
tion behavior.”
11.  In Appendix 2, the following note has been added to the footnote: “This table represents the 
relationships of reviewers with industry and other entities that were self-disclosed at the time 
of peer review. It does not necessarily reflect relationships with industry at the time of publi-
cation. To review the NHLBI and ACC/AHA’s current comprehensive policies for managing 
relationships with industry and other entities, please refer to http://www.nhlbi.nih.gov/guide-
lines/cvd_adult/coi-rwi_policy.htm and http://www.cardiosource.org/Science-And-Quality/
Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx.”
12.  In Appendix 3, (Appendix 6 in published document), the table note “Risk calculators noted 
above include hyperlinks to the respective webpage” has been deleted.
